Poster Presentations

Poster Session P01. Preclinical models

P01.01 | Orthotopic HCC Mouse Models to Predict Response to Immunotherapy
C. Hage1, S. Hoves1, M. Ashoff1, L. Strauss1, M. Perro2, F. Herting1, F. Kiessling3, T. Pöschinger1; 1Roche Innovation Center Munich, Penzberg, Germany, 2Roche Innovation Center Zurich, Zurich, Switzerland, 3RWTH Aachen University, Aachen, Germany.

P01.02 | A new family of potent TLR9 agonists, EnanDIM, which inhibit tumor growth in various syngeneic murine models
B. Volz1, K. Kapp1, D. Oswald1, B. Wittig2, M. Schmidt1; 1Mologen AG, Berlin, Germany, 2Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet Berlin, Berlin, Germany.

P01.03 | Building Kras (G12D)/Trp53 null/Pdx1-cre (KPC) mouse allograft tumor model for efficacy evaluation of combinatory immunotherapie
Y. Song, B. Liu, A. Xiaoyu An, L. Zhang, J. Cai, Q. Shi, H. Qixiang Li, D. Xuesong Ouyang; Crown Bioscience, San Diego, CA, United States.

P01.04 | Preclinical development of a therapeutic antibody for the treatment of epithelial ovarian carcinoma
M. Suarez-Carmona1, D. S. Ferber1, F. Momburg2, M. Meyer2, M. Hampel1, B. M. Lenoir1, S. Schott3, I. Zörnig1, D. Jäger1, N. Halama1; 1National Center for Tumor Diseases (NCT), Heidelberg, Germany, 2Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany, 3Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

P01.05 | A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant
C. S. Ozverel1, I. Karaboz1, A. Nalbantsoy2; 1Biology Department, Faculty of Science, Ege University, Izmir, Turkey, 2Bioengineering Department, Faculty of Engineering, Ege University, Izmir, Turkey.

P01.06 | Human tissue explant cultures from ovarian carcinoma resectates: an innovative, high-predictive link between basic research and clinical trial
M. Hampel1, A. Heinzelmann1, M. Suarez-Carmona1, U. Prüfer1, S. Schott2, S. Eismann2, I. Zörnig1, D. Jäger1, N. Halama1; 1National Center for Tumor Diseases, Heidelberg, Germany, 2Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

 

Poster Session P02.Tumor Immunity and Microenvironment

P02.01 | Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab
C. Jensen1,2, D. Madsen3, M. Hansen3, H. Schmidt4, I. Svane3, M. Karsdal1, N. Willumsen1; 1Biomarkers & Research, Nordic Bioscience, Herlev, Denmark, 2Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark, 3Center for Cancer Immune Therapy, Department of Haematology and Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev, Denmark, 4Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

P02.02 | Humanized Mouse Models of Triple-Negative and Triple-Positive Breast Cancer for Preclinical Validation of Novel Immuno-Oncology Therapies
T. E. Kähkönen1, M. I. Suominen1, J. M. Halleen1, T. Haapaniemi2, A. Tanaka3, M. Seiler3, J. Bernoulli1; 1Pharmatest Services, Turku, Finland, 2BioSiteHisto Ltd, Tampere, Finland, 3Taconic Biosciences, Hudson, NY, United States.

P02.03 | Cancer cells regulate Interleukin-22 production to promote tumor growth
C. Voigt1, P. May1, A. Gottschlich1, A. Markota1, D. Wenk1, I. Gerlach1, J. Suárez Gosálvez1, T. Ruzicka1, A. Kraechan1, S. Voigt2, G. Stathopoulos3,4, K. Arendt3, C. Heise1, F. Rataj1, K. Janssen5, M. Königshoff3, H. Winter6, I. Himsl2, W. Thasler2, M. Schnurr1, S. Rothenfußer1, S. Endres1, S. Kobold1; 1Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany, 2Brustzentrum Klinikum Dritter Orden, Munich, Germany, 3Comprehensive Pneumology Center, Ludwig Maximilian University of Munich, Munich, Germany, 4Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, University of Patras, Rio, Greece, 5Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany, 6Department of Thoracic Surgery, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

P02.04 | Omental fat in ovarian cancer induces lymphangiogenesis
D. Ferber*1, B. Lenoir*1, M. Suarez-Carmona1, S. Schott2, I. Zörnig1, D. Jäger1, N. Halama1; 1National Center for Tumor Diseases, Heidelberg, Germany, 2Heidelberg University Hospital, Heidelberg, Germany.

P02.05 | Spatial profiling and functional phenotyping of mast cell distribution in human cancer tissues
D. Ferber1, M. Suarez-Carmona1, J. N. Kather1, B. Lenoir1, M. Hampel1, U. Prüfer1, S. Eismann2, S. Schott2, I. Zörnig1, D. Jäger1, N. Halama1; 1Medical Oncology, National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany, 2Department of Obstetrics and Gynaecology, Heidelberg University Hospital, Heidelberg, Germany.

P02.06 | Digital spatial profiling platform allows for spatially- resolved, multiplexed measurement of solid tumor protein distribution and abundance in FFPE tissue sections
A. Winfield; Nanostring, Seattle, WA, United States.

P02.07 | In vitro Culture of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy in Breast Cancer Patients
s. seber1,2, t. yetisyigit1,2, b. turgut3,2, S. Bulus4,5, S. Ozkan Gürdal6,2, M. Oznur7,2; 1Medical Oncology Deparment, Tekirdag, Turkey, 2Namik Kemal University Hospital, Tekirdag, Turkey, 3Hematology Deparment, Tekirdag, Turkey, 4Hematology Laboratory, Tekirdag, Turkey, 5Namik Kemal University Hospital, Tekirdağ, Turkey, 6General Surgery Department, Tekirdag, Turkey, 7Pathology Deparment, Tekirdag, Turkey.

P02.08 | The role of myeloid-derived suppressor cells in autologous hematopoietic stem cell transplantation
A. Betsch1, O. Rutgeerts1, S. Fevery1, B. Sprangers2, D. Dierickx2, M. Beckers2; 1KU Leuven, Leuven, Belgium, 2UZ Leuven, Leuven, Belgium.

P02.09 | Standard normoxic versus physiological hypoxic culture of AML patients'(pts)whole blood(WB) samples with immunemodulatory Kits yields comparable proportions of Dendritic cells and functional results
F. Doraneh gard1, D. Amberger1, M. Weinmann1, C. Boeck1, C. Gunsilius1, C. Kugler1, J. Werner2, D. Kraemer3, A. Rank4, C. Schmid4, H. Schmetzer1; 1University Hospital of LMU, Department for Hematopoietic cell Transplantations, Med3, munich, Germany, 2University Hospital of Tuebingen, Department for Hematology and Oncology, Tuebingen, Germany, 3University Hospital of Oldenburg, Department for Hematology and Oncology, Oldenburg, Germany, 4Municipal Hospital of Augsburg, Department of Hematology and Oncology, Augsburg, Germany.

P02.10 | Insights into the tumor microenvironment and human TRBV gene polymorphism revealed by long-amplicon immune repertoire sequencing
G. M. Lowman1, T. Looney2, A. Glavin2, E. Linch1, L. Miller1, D. Topacio-Hall1, S. Pabla3, S. Glenn3, A. Pankov2, J. Zheng2, R. Hartberg4, H. Almåsbak4, T. E. Stav-Noraas4, A. Kullmann4, J. Conroy3, C. Morrison3, F. Hyland2, M. Andersen1; 1Thermo Fisher Scientific, Carlsbad, CA, United States, 2Thermo Fisher Scientific, South San Francisco, CA, United States, 3OmniSeq, Inc., Buffalo, NY, United States, 4Thermo Fisher Scientific, Oslo, Norway.

P02.11 | Tumor-specific neoantigens drive T-cell clonotype convergence
J. C. Machado1, J. Reis1, M. Fernandes2, R. Silva1, L. Cirnes1, F. Carneiro3, J. L. Costa1; 1IPATIMUP, Porto, Portugal, 2Centro Hospitalar de São João, Porto, Portugal, 3Faculty of Medicine, Porto, Portugal.

P02.12 | Solubleimmune checkpoints CD27, Lag3, PD-L2 and Tim3 in early stage NSCLC patients
G. Gamerith1,2, H. Hackl3, P. Wallinger1,2, L. Fandel1,2, J. Kern2, F. Augustin4, E. Lorenz1,2, E. Hoflehner1,2, F. Mildner1,2, P. Moser5, S. Sprung6, B. Zelger6, S. Köck1,2, A. Amann1,2, G. Schäfer6, D. Öfner4, H. Maier4, Z. Trajanoski3, H. Zwierzina1,2, S. Sopper1,2; 1Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, 2Tyrolean Cancer Research Institute, Innsbruck, Austria, 3Medical University of Innsbruck, Biocenter, Division of Bioinformatics, Innsbruck, Austria, 4Medical University of Innsbruck, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck, Austria, 5LKH Innsbruck, Institute of Pathology, Innsbruck, Austria, 6Medical University of Innsbruck, Department of Pathology, Innsbruck, Austria.

P02.13 | The influence of stromal cells on CD3+CD8+ tumorinfiltrating lymphocyte subpopulations in cancer microtissues
S. Koeck1,2, M. Zwierzina3, G. Gamerith1,2, E. Lorenz1,2, H. Zwierzina1,2, J. Kern1,2, A. Amann1,2; 1Medical University of Innsbruck, Department of Internal Medicine V, Innsbruck, Austria, 2Tyrolean Cancer Research Institute, Innsbruck, Austria, 3Medical University of Innsbruck, Department of Plastic, Reconstructive and Aesthetic Surgery, Innsbruck, Austria.

 

Poster Session P03.Primary and Acquired Resistance mechanisms

P03.01 | The role of TopoisomeraseII-α (TOPO IIA) as apredictivefactorfor response to neoadjuvant anthracyclines based chemotherapy in locally advancedbreast cancer
M. M. Gamea; Aswan University, Tanta, Egypt.

P03.02 | MiRNA set dysregulation in breast cancer cells can contribute to both primary and acquired resistance to immune checkpoint blockade
V. A. Halytskiy; Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kiev, Ukraine.

 

Poster Session P04.Therapeutic modulation of immune checkpoints

P04.01 | Complete clinical remission of stage IV breast cancer with liver, lung, bone and lymph node metastasis combining low-dose checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia and metronomic low-dose chemotherapy
R. Kleef; Ralf Kleef Immunology & Integrative Oncology, Vienna, Austria.

P04.02 | Local oncothermia (modulated-electrohyperthermia) against systemic malignancy
A. Szasz, N. Meggyeshazi, E. Borbenyi, R. Mohacsi, T. Garay, P. Torgyik, M. V. Dank; Semmelweis Univeristy, Budapest, Hungary.

P04.03 | AB680, a potent and selective CD73 small molecule inhibitor, reverses the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors
U. Schindler, A. Becker, K. Lawson, L. Jin, J. Jeffrey, J. Kalisiak, F. Yin, K. Zhang, A. Chen, D. Swinarski, M. J. Walters, S. Young, J. P. Powers, J. Tan; Arcus Biosciences, Hayward, CA, United States.

P04.04 | AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy
U. Schindler, L. Seitz, D. Ashok, D. Piovesan, J. Tan, D. DiRenzo, F. Yin, M. Leleti, B. Rosen, D. Miles, L. Jin, T. Park, S. Young, F. Soriano, A. Rieger, J. Karakunnel, E. Sharif, J. P. Powers, M. J. Walters; Arcus Biosciences, Hayward, CA, United States.

P04.05 | Immune Modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinicall approved Response Modifiers inmproves clinical status, bloodcellregeneration and gives rise to leukemiaspecific adaptive and innate immune reactive cells
C. Schmid1, M. Atzler2, A. Rank3, M. Inngjerdingen4, A. Rabe2, D. Deen2, R. Wang2, B. Eiz-Vesper5, H. Schmetzer6; 1Dept Med II, Hematopoetic stem cell transplantation, Augsburg University, 86156 Augsburg, Germany, 2Hematopoetic Cell Transplantation Unit,Dept of Med3,, 81377 Munich, Germany, 3Dept of MedII, Section of Hematopoetic Cell Transplantations, University of Augsburg, 86156 Augsburg, Germany, 4Dept Immunology, Oslo University Rikshospitalet, 0027 Oslo, Norway, 5Institute for Transfusion-Medicine, Hannover Medical School, 30625 Hannover, Germany, 6Hematopoetic Cell Transplantation Unit,Dept of Med3, University Hospital of Munich, 81377 Munich, Germany.

 

Poster Session P05. Combination therapy

P05.01 | Engineering high affinity, soluble T cell receptors for the treatment of cancer
L. Holt, N. Liddy, G. Bossi, J. Harper, J. Dukes, S. Paston, T. Mahon, P. Molloy, M. Sami, E. Baston, B. Cameron, A. Powesland, A. Johnson, N. Hassan, A. Vuidepot, C. Coughlin, B. Jakobsen; Immunocore Ltd, Abingdon, United Kingdom.

P05.02 | 4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for cancer immunotherapy
S. Hamm, T. H. Wulff, K. Kronthaler, S. Schrepfer, U. Parnitzke, A. H. Bretz; 4SC AG, Planegg-Martinsried, Germany.

P05.03 | Peritumoral gene electrotransfer of interleukin-12 as an adjuvant immunotherapy to intratumoral electrochemotherapy for murine melanoma treatment
K. Ursic1, S. Kos1, U. Kamensek1, M. Cemazar1,2, G. Sersa1,3; 1Institute of Oncology Ljubljana, Department of Experimental Oncology, Ljubljana, Slovenia, 2University of Primorska, Faculty of Health Sciences, Izola, Slovenia, 3University of Ljubljana, Faculty of Health Sciences, Ljubljana, Slovenia.

P05.04 | P-MAPA immunotherapy and interleukin-12 on ovarian carcinoma SKOV-3 cells: assessment of the TLR signaling and cytokine/chemokine profile.
L. Chuffa, L. Lupi, M. Cucielo, F. Martinez, F. Delella, W. Fávaro; Institute of Bioscience of Botucatu, Botucatu, Brazil.

P05.05 | Impact of natural substances on the efficacy of immunotherapy
M. Luzbetak, N. Süßenguth, B. Mayer; AVT Surgery, Klinikum Großhadern, Munich, Germany.

 

Poster Session P06. Anti-cancer vaccines

P06.01 | Novel PAP-derived vaccine for the treatment of advanced prostate cancer
P. Le Vu1, J. Vadakekolathu1, H. Nicholls1, D. Christensen2, L. Durrant3, A. Pockley4, S. E. McArdle1; 1The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom, 2Statens Institut, Copenhagen, Denmark, 3Clinicla Oncology, Nottingham University, Nottingham, United Kingdom, 4The john van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom.

P06.02 | HAGE-derived peptide as a vaccine to prevent relapse in TNBC patients: Proof of concepts
D. Nagarajan1, L. Durrant2, G. Pockley1, S. McArdle1; 1NTU, Nottingham, United Kingdom, 2Scancell Holding plc, Nottingham, United Kingdom.

P06.03 | Eliciting protective T cell immunity against EBV-associated malignancies by vaccination
J. Rühl1, C. Citterio1, C. Leung2, C. Münz1; 1Institute of Experimental Immunology, Zürich, Switzerland, 2Department of Hematology, University College London Cancer Institute, London, United Kingdom.

 

Poster Session P07. Adoptive cell therapy

P07.01 | Proof of concept and mode of action of a novel modular platform for adoptive T cell therapy combining bispecific antibodies with synthetic agonistic receptors
C. Karches1, M. Benmebarek1, M. Schmidbauer1, M. Kurzay1, R. Klaus1, M. Geiger2, S. Lesch1, B. Cadilha1, F. Rataj1, C. Heise1, R. Murr2, J. vom Berg3, M. Jastroch4, D. Lamp4, P. Duewell1, G. Niederfellner5, C. Sustmann5, S. Endres1, C. Klein2, S. Kobold1; 1Division of Clinical Pharmacology, München, Germany, 2Roche Innovation Center Zurich, Schlieren, Switzerland, 3Institute of Laboratory Animal Science, Zurich, Switzerland, 4Helmholtz Diabetes Center and German Diabetes Center (DZD), München, Germany, 5Roche Innovation Center Munich, Penzberg, Germany.

P07.02 | Mesothelin-targeted bispecific antibodies drive synthetic agonistic receptor – transduced T cells to mediate specific and conditional therapy of human pancreatic cancer models
M. Benmebarek1, C. Karches1, M. Schmidbauer1, M. Kurzay1, R. Klaus1, M. Geiger2, F. Rataj1, B. Cadilha1, J. Keyl1, S. Lesch1, C. Heise1, R. Murr2, J. vom Berg3, M. Jastroch4, D. Lamp4, G. Niederfellner5, C. Sustmann5, S. Endres1, C. Klein2, S. Kobold1; 1Division of Clinical Pharmacolog, LMU, Munich, Germany, 2Roche Innovation Centre Zurich, Schlieren, Switzerland, 3Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland, 4Helmholtz Diabetes Center and German Diabetes Center (DZD), Helmholtz Zentrum München, Munich, Germany, 5Roche Innovation Centre, Penzberg, Germany.

P07.03 | Cytokine-Induced Killer cells combined with anti EGFR monoclonal antibody abrogate triple negative breast cancer metastatization
R. Sommaggio1, E. Cappuzzello1, A. Rosato1,2; 1Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy, Padua, Italy, 2Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy, Padua, Italy.

P07.04 | Depletion of MDSC improves the anti-neuroblastoma effect of adoptive recipient leukocyte infusion in allogeneic bone marrow transplanted mice.
I. Dierckx de Casterlé1, O. Rutgeerts1, S. Fevery1, S. Van Gool2, M. Waer1, A. D. Billiau1, B. Sprangers3; 1KU Leuven, Leuven, Belgium, 2Immunologisches Onkologisches Zentrum Köln, Köln, Germany, 3KU Leuven ; University Hospitals Leuven, Leuven, Belgium.

P07.05 | Arming T cells with activating FcγRIIIa receptors for antibody redirected lysis of cancer cells
S. J. Jacobi1, F. Rataj1, F. Asang1, S. Stoiber1, M. Benmebarek1, R. Klaus1, S. Endres1, C. Klein2, S. Kobold1; 1Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Munich, Germany, 2Roche Innovation Center Zurich, Schlieren, Switzerland.


Poster Session P08.  Monitoring of immunotherapy

P08.01 | How cancer specific T-cell recognition and functionality is affected by combination of radio- and immunotherapeutic strategies
T. S. Meldgaard, L. R. Petersen, T. K. Pedersen, A. Bjerregaard, A. M. Marquard, A. E. Hansen, T. L. Andresen, S. R. Hadrup; National Veterinary Institute, Kongens Lyngby, Denmark.

P08.02 | CD73 activity and outcome of advanced melanoma patients treated with nivolumab
S. Morello1, C. Sorrentino2, M. Capone3, D. Giannarelli4, G. Madonna3, D. Mallardo3, A. M. Grimaldi3, A. Pinto1, P. A. Ascierto3; 1Department of Pharmacy, University of Salerno,, Salerno, Italy, 2Department of Pharmacy, University of Salerno, PhD Program in Drug Discovery and Development, Salerno, Italy, 3Melanoma, Cancer Immunotherapy and Innovative Therapies O.U., National Cancer Institute “G. Pascale”, Naples, Italy, 4Regina Elena National Cancer Institute, Rome, Italy.

P08.03 | Immuno-related adverse events from Check-Point inhibitors during immune-therapy for cancer. Imaging Findings
F. Sandomenico1, G. De rosa2, S. Pizza2, O. Catalano1, S. Setola1, E. Simeone3, L. Festino3, A. Grimaldi3, V. Vanella3, A. Petrillo1, P. Ascierto3; 1National Cancer Institute – IRCCS ” G.Pascale Foundation”, Department of Radiology, Naples, Italy, 2University of Naples Federico II, Department of Advanced Biomedical Science, Naples, Italy, 3National Cancer Institute – IRCCS ” G.Pascale Foundation”, Unit of Medical Oncology and Innovative Therapy, Naples, Italy.

P08.04 | Positive controls for cytometric in vitro T cell activation test for bladder carcinoma patient stratification and monitoring
P. Hadlova, A. Koladiya, K. Drbal; Charles University, Praha, Czech Republic.

 

Poster Session P09.  Young Researcher Session

P09.01 | Trends in incidence of head and neck cancers in India
D. Francis; Tagore dental College and Hospital, Chennai, India.

P09.02 | Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives
E. Cappuzzello1, R. Sommaggio1, C. Kellner2, M. Peipp2, A. Rosato1,3; 1Department of Surgery, Oncology and Gastroenterology, Immunology and Oncology Section, University of Padua, Padua, Italy, 2Division of Stem Cell Transplantation and Immunotherapy, 2° Department of Medicine, Christian-Albrechts-University, Kiel, Germany, 3Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.

P09.03 | Exploring phenotypic and functional characteristics of cultured tumor infiltrating lymphocytes
M. Rana1, T. Borch1,2, A. Draghi1, A. Gokuldass1, M. Donia1,2, I. Svane1,2; 1Center for Cancer Immune therapy (CCIT), Copenhagen, Denmark, 2Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark, Copenhagen, Denmark.

P09.04 | A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors
J. Medina, M. Hinterberger, M. Testori, M. Geiger, R. Giessel, B. Bathke, R. Kassub, F. Graebnitz, G. Fiore, P. Chaplin, H. Hochrein, H. Lauterbach; Bavarian Nordic GmbH, Planegg, Germany.

P09.05 | Expression of CD73 on MDSCs and CD8+/PD-1+ cells as new possible biomarkers for advanced melanoma patients treated with nivolumab
F. Fratangelo1, S. Morello2, G. Madonna1, M. Capone1, D. Mallardo1, R. Falcone1, A. M. Grimaldi1, E. Simeone1, V. Vanella1, D. Giannarelli3, C. Sorrentino2, A. Pinto2, P. A. Ascierto1; 1S.C. Oncologia Clinica Sperimentale Melanoma Immunoterapia e Terapie Innovative – IRCCS – Fondazione G. Pascale, Naples, Italy, 2Dipartimento di Farmacia, Università di Salerno, Fisciano, Italy, 3Istituto Nazionale Tumori Regina Elena, Rome, Italy.

P09.06 | M1 polarization of tumor-associated macrophages after irradiation of human rectal cancer in patients and 3D co-culture model
V. Stary1, J. Strobl2, A. Beer3, H. Dolznig4, M. Bergmann1; 1Department of Surgery, Medical University of Vienna, Vienna, Austria, 2Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria, 3Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria, 4Institute of Genetics, Medical University of Vienna, Vienna, Austria.